Cheplapharm Arzneimittel GmbH has notified AIFA and EMA that the shortage of Visudyne (verteporfin, powder for solution for injection, 15 mg) will continue until the of 2026 in all EU/EEA countries.

Consequently, the current approach of reduced and controlled deliveries will continue for the foreseeable future.

Healthcare professionals are advised to take the limited availability of Visudyne into account when planning, prioritising and prescribing treatments. In addition, Healthcare professionals are required to coordinate with relevant health authorities and follow their guidance, where applicable, to ensure patients at greatest need receive therapy.